Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled …

A Blauvelt, K Reich, M Lebwohl, D Burge… - Journal of the …, 2019 - Wiley Online Library
Abstract Background Certolizumab pegol, an Fc‐free, PEG ylated, anti‐tumour necrosis
factor (TNF) biologic, has demonstrated favourable results in three ongoing, phase 3 …

Pregnancy & neonatal outcomes in spondyloarthritis

S Maguire, A Molto - Best Practice & Research Clinical Rheumatology, 2023 - Elsevier
Limited research has been conducted on the impact of spondylitis (SpA) on fertility, but some
studies suggest a higher risk of subfertility in women with SpA compared to the general …

Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis

K Fahrbach, G Sarri, DM Phillippo, B Neupane… - Dermatology and …, 2021 - Springer
Introduction Many targeted, systemic therapies have been developed for treatment of
moderate-to-severe psoriasis (PsO). A network meta-analysis (NMA) allows for comparison …

[HTML][HTML] [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on …

JM Carrascosa, L Puig, IB Romero… - Actas dermo …, 2022 - Elsevier
Background and objectives Since its inception, the Psoriasis Group (GPs) of the Spanish
Academy of Dermatology and Venereology (AEDV) has worked to continuously update …

The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy …

I Giles, I Thorne, NS Schmidt, C Reid… - The Lancet …, 2024 - thelancet.com
Active inflammatory arthritis in pregnancy is associated with an increased risk of adverse
pregnancy outcomes. Treatment of active inflammation and maintenance of low disease …

[PDF][PDF] Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic …

D Prieto-Peña, M Calderón-Goercke, A Adán… - Clin Exp …, 2021 - researchgate.net
Methods We carried out a multicentre study of women with uveitis who received CZP during
pregnancy and their neonates. The main visual outcomes were visual acuity (VA) …

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

U Lindström, B Glintborg, D Di Giuseppe… - …, 2021 - academic.oup.com
Objectives To compare treatment retention and response to secukinumab vs adalimumab,
including the other four TNF inhibitors (TNFi) as comparators, in PsA. Methods All patients …

State-of-The-art review of pregnancy-related psoriasis

AA Simionescu, BM Danciu, AMA Stanescu - Medicina, 2021 - mdpi.com
Psoriasis is a chronic immunologic disease involving inflammation that can target internal
organs, the skin, and joints. The peak incidence occurs between the age of 30 and 40 years …

Clinical practice of adalimumab and infliximab biosimilar treatment in adult patients with Crohn's disease

W Reinisch, K Gecse, J Halfvarson… - Inflammatory bowel …, 2021 - academic.oup.com
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the
treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with …

Pathogenesis-oriented therapy of psoriasis using biologics

WH Boehncke, NC Brembilla - Expert Opinion on Biological …, 2022 - Taylor & Francis
Introduction Psoriasis is currently regarded an immune-mediated inflammatory disease. The
central pathogenic axis comprises interleukin-23, TH17-lymphocytes differentiating under its …